CTOs on the Move

Essentia Biosystems

www.essentiabio.com

 
Essentia Biosystems is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Diasome Pharmaceuticals Inc

Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity.

Glycomine

There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA approved treatment. Glycomine develops therapeutics for diseases which have no treatment options.

Applied Technology Holdings

ATH's sales and technology groups build custom wireless turn-key technology solutions that relate to specific customer body motion measurement needs and market opportunities. ATH's vision is to commercialize it's patent portfolio and lead the industry in distributed wireless bioMotion technology and data capture processes. Founded in 2005, Applied Technology Holdings Inc., is a hardware and software maker specializing in wireless bioMotion monitoring systems for medical, sports, gaming, military and aviation applications. ATH's subsidiaries are experts in supporting the solution provider platforms for easy integration into the target markets. Other ATH companies participate in the Sports, Medical, Gaming, Aviation, and Military market opportunities and segments.

Progressive Medical

Progressive Medical is a Westerville, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in a Phase 3 clinical trial enrolling patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for five additional years of QIDP market exclusivity in the event of U.S. approval. It is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes and topical hydrogels. The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.